The Log
Archive
733 stories, newest first.
May 2026
- May 21Science & Medicine
Daily Pulse: One Year After the Lykos Rejection, the Psychedelic Field Is Quieter — and More Methodical
A year after the FDA's rejection of Lykos's MDMA-assisted therapy for PTSD, the psychedelic industry has quietly restructured. Lykos has cut 75% of its headcount; its CEO has stepped down; the rest of the field is pivoting toward conventional Phase III rigor.
- May 21Science & Medicine
Daily Pulse: Adding CBT to GLP-1 Drugs Further Cuts Heavy Drinking, NIH Reports
A new NIH summary of research finds that combining GLP-1 receptor agonists with cognitive behavioral therapy reduces heavy drinking more than either alone — the strongest case yet for treating alcohol use disorder with a medication and a behavioral therapy as a single integrated treatment.
- May 21Harm Reduction
Substance Spotlight: The Drug Supply Stops Being Just Fentanyl
The May 12 DEA advisory describes a supply in which fentanyl is one ingredient among several. Here is what that changes — for naloxone, for overdose response, and for the families learning both for the first time.
- May 21Arizona Watch
Three Arizona Headwinds in One Week: What the May Data Actually Says About Our State
National overdoses dropped 14 percent. Arizona's rose 17.31 percent. In one week, three pieces of news show why our state can no longer point to the national curve as the story.
- May 8Science & Medicine
Novel & Emerging Psychoactives: Xylazine, Nitazenes, Kratom, Tianeptine
Novel psychoactive substances in 2026 — xylazine, medetomidine, nitazenes, kratom, tianeptine, designer benzos: emerging supply patterns and harm profiles.
- May 8Science & Medicine
Inhalants: The Substance Class Nobody Talks About
Inhalants in 2026 — volatile solvents, aerosols, nitrites, nitrous: the overlooked class with 'sudden sniffing death' risk and youth-first use patterns.
- May 8Science & Medicine
Nicotine & Tobacco in 2026
Nicotine and tobacco in 2026 — combustible tobacco, vaping, nicotine pouches: the science, the policy, the FDA-approved cessation meds, and what's working.
- May 8Science & Medicine
Psychedelics & Empathogens in 2026
Psychedelics and empathogens in 2026 — psilocybin, LSD, MDMA, ibogaine, DMT: pharmacology, addiction treatment research, policy, and the risks the hype overlooks.
- May 8Science & Medicine
Dissociatives: Ketamine, PCP, DXM, Nitrous
Dissociatives in 2026 — ketamine (therapeutic + recreational), PCP, DXM, nitrous oxide: pharmacology, ketamine-assisted therapy evidence, and emerging use disorder.
- May 8Science & Medicine
Cannabinoids in 2026: From Flower to Delta-8 to Synthetic Spice
Cannabinoids in 2026 — cannabis, high-potency concentrates, synthetic cannabinoids, and the unregulated Delta-8/HHC hemp products: what's actually known.
- May 8Science & Medicine
Non-Opioid Depressants: Benzos, Z-Drugs, and the Ones You Didn't Know About
Non-opioid depressants in 2026 — benzodiazepines, Z-drugs, barbiturates, GHB: pharmacology, dependency, tapering, and designer benzo trends.
- May 8Science & Medicine
Alcohol: The Most Widely Used Drug in America, Explained
Alcohol pharmacology, biology, policy, and treatment in 2026 — including the three FDA-approved medications for alcohol use disorder and why they're underused.
- May 8Science & Medicine
Stimulants in 2026: Meth, Cocaine, and the Prescription Shadow
Stimulants in 2026 — meth, cocaine, and prescription stimulants: pharmacology, health effects, policy, trends, and what actually treats stimulant use disorder.
- May 8Science & Medicine
Opioids: The Definitive 2026 Guide
The 2026 definitive guide to opioids — pharmacology, brain effects, addiction mechanisms, policy, trends, treatment, and harm reduction.
- May 8Technology & Innovation
Pelago, Boulder, Workit, Ophelia — Who's Who in Digital Recovery
A reader-friendly map of the major digital recovery companies in 2026 — Pelago, Boulder Care, Workit, Ophelia, and others — and how they differ.
- May 8Treatment & Recovery
How 211 Fills the Gaps SAMHSA's Directory Can't
Why 211 is an essential companion to SAMHSA's directory — the nonclinical recovery services that make treatment stick.
- May 8Science & Medicine
What the Evidence Says About Psychedelic-Assisted Therapy for Addiction in 2026
An evidence review of psychedelic-assisted therapy for substance use disorder in 2026 — psilocybin, MDMA, ibogaine, ketamine, and the open questions.
- May 8Harm Reduction
Xylazine: What It Is, and Why It's Changing Overdose Response
Xylazine ("tranq") is a veterinary sedative now widely cut into the fentanyl supply. What it is, why naloxone only partly works, and how to respond.
- May 8Policy & Funding
DEA Extends Telemedicine Buprenorphine Rules Through 2026
DEA and HHS extended telemedicine prescribing flexibilities through 2026, and made telehealth buprenorphine permanent for 6 months of care.
- May 8Arizona Watch
The Arizona Opioid Settlement, Explained
Arizona's $1.215B opioid settlement, explained — state vs. county shares, how funds are spent, and what Maricopa County has funded so far.
- May 8Treatment & Recovery
MAT in 2026: What Medication-Assisted Treatment Is (and What It Isn't)
MAT in 2026, explained: how buprenorphine, methadone, and naltrexone work, who they're for, and the myths that keep people away.
- May 8The Crisis, By the Numbers
The Treatment Gap: Why Only 1 in 7 Americans with SUD Get Help
Why only 15% of Americans with SUD get treatment — the five structural reasons behind the treatment gap and what would fix them.
- May 8The Crisis, By the Numbers
Alcohol: America's Quieter Epidemic
Alcohol-induced deaths in the U.S. reached 105,400 in 2022, up 30% since the pandemic. The quiet half of the crisis.
- May 8The Crisis, By the Numbers
Fentanyl, Still Driving Overdose Deaths in 2026
Updated 2026 fentanyl data: share of overdose deaths, polysubstance patterns, and why the illicit supply is becoming more complex.